Orthofix (OFIX) operations chief sells 2,559 shares for RSU tax withholding

Rhea-AI Filing Summary

Orthofix Medical Inc. executive Aviva McPherron, President of Global Operations & Quality, reported selling a total of 2,559 shares of common stock in open-market transactions on March 4 and 5, 2026.

According to the disclosure, these sales were executed to satisfy tax withholding obligations related to the settlement of restricted stock units under a pre-approved, mandatory sell-to-cover program established by the Board’s Compensation and Talent Development Committee, and were carried out without any discretionary trading decision by the reporting person. After these transactions, McPherron directly owns 67,853 shares of Orthofix common stock, which includes 54,692 previously reported restricted stock units.

Insider Trade Summary

Net Seller: 2,559 shares ($32,591)

Net Sell 2 txns

Insider McPherron Aviva

Role Pres, Global Ops & Qual

Sold 2,559 shs ($33K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,263	$12.5508	$16K
Sale	Common Stock	1,296	$12.9163	$17K

Holdings After Transaction: Common Stock — 67,853 shares (Direct)

Footnotes (1)

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. Includes 54,692 previously reported restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McPherron Aviva

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres, Global Ops & Qual

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		1,296	D	$12.9163(2)	69,116(3)	D
Common Stock	03/05/2026		S(1)		1,263	D	$12.5508(4)	67,853(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

3. Includes 54,692 previously reported restricted stock units.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

	/s/ J. Andres Cedron, Attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Orthofix (OFIX) executive Aviva McPherron report in this Form 4?

Aviva McPherron reported selling a total of 2,559 Orthofix common shares in open-market transactions. The sales occurred on March 4 and 5, 2026 and were tied to tax withholding obligations from restricted stock unit settlements.

How many Orthofix (OFIX) shares did Aviva McPherron sell and at what prices?

McPherron sold 1,296 shares at a weighted average price of $12.9163 on March 4, 2026, and 1,263 shares at a weighted average price of $12.5508 on March 5, 2026, for a combined sale of 2,559 shares.

Why were Aviva McPherron’s Orthofix (OFIX) shares sold according to the Form 4?

The shares were sold to satisfy tax withholding obligations arising from the settlement of restricted stock units. The filing explains this was done under a pre-existing, mandatory sell-to-cover requirement approved by Orthofix’s Compensation and Talent Development Committee.

Did Aviva McPherron exercise discretion over the Orthofix (OFIX) share sales?

No. The filing states the sale was made without the exercise of any discretion by McPherron. It followed a previously approved, mandatory sell-to-cover program administered by the Board committee overseeing the equity compensation plan.

How many Orthofix (OFIX) shares does Aviva McPherron hold after these transactions?

After the reported sales, McPherron directly owns 67,853 Orthofix common shares. This total includes 54,692 previously reported restricted stock units, as indicated in the footnotes to the Form 4 filing.

What role does Aviva McPherron hold at Orthofix (OFIX)?

Aviva McPherron serves as President, Global Operations & Quality at Orthofix Medical Inc. This officer role is identified in the Form 4, which reports her equity-related transactions and resulting ownership in the company’s common stock.